Mariama C. Maiga

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis

W. Bishai, M. Maiga, B. Ahidjo, 2015, Antimicrobial Agents and Chemotherapy.

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.

W. Bishai, M. Polis, N. Ammerman, 2013, The Journal of infectious diseases.

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis

W. Bishai, F. Bougoudogo, M. Maiga, 2015, EBioMedicine.

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

W. Bishai, Shashank Gupta, S. Tyagi, 2013, American journal of respiratory and critical care medicine.

In Vitro and In Vivo Studies of a Rapid and Selective Breath Test for Tuberculosis Based upon Mycobacterial CO Dehydrogenase

W. Bishai, Z. Sharp, V. Atudorei, 2014, mBio.

The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

W. Bishai, B. Andrade, A. Ordonez, 2016, JCI insight.